Transcript of Earnings Conference Call for the Q4FY25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals held its first earnings call, reporting standalone FY25 revenue of INR318.7 crores (+19.8% YoY) and EBITDA of INR48.14 crores (+17%), with margins flat at 15.9%. Consolidated revenue grew 32% to INR352 crores, boosted by Innoxel milestone income and Varenyam Healthcare consolidation. Key highlight: subsidiary Innoxel Lifesciences (CDMO arm, 56% stake) cleared its first USFDA inspection with only one minor observation, with EU GMP audits lined up for H1 FY26. Management expects ~INR70 crores in licensing/milestone revenue from Innoxel in FY26 and aims for ~30% net margins at full ramp-up. The product pipeline stands at 22 complex injectable/505b2 molecules, with 10 already partnered, targeting expansion to 40-45 products over 3-4 years. Subsidiary Varenyam Biolifesciences (project cost INR120-150 crores, INR30 crores spent) is on track to be operational by 2027 for emerging regulated markets.
Positive for shareholders – USFDA clearance of Innoxel is a major milestone unlocking high-margin regulated market opportunities, and explicit margin guidance (~30% net at Innoxel at peak) plus pipeline visibility (INR70 crores near-term milestone revenue) supports the long-term growth thesis. The stock could see positive momentum as Innoxel's commercial ramp-up progresses.